NeuroAge Therapeutics

NeuroAge is not currently hiring. If you receive a message offering you a job from someone supposedly at NeuroAge, that's not us, it's a scam. Please don't interact with them or give them any sensitive information.

Apply to present your poster at the Longevity Global Summit Dec. 3-4th, at the Buck Institute for Research on Aging.   Do you have a groundbreaking project that's moving forward? This is your chance to showcase your results to a global audience of industry leaders, investors, and fellow visionaries.   🗓️ Apply to present here: https://lnkd.in/gKfkGDr9 📅 Don’t miss out! Grab your tickets while they last: https://lnkd.in/gx8Q8mYT

All good ways to slow brain aging as well. Sounds like a great Sunday ☀️

Are you an investor interested in #longevity biotech/healthtech/deep tech looking to meet some amazing founders? Do you want a complimentary VIP ticket to the Longevity Summit Dec 3-4th at the Buck where many of these companies are presenting? DM me for your complimentary ticket and a warm intro to the companies speaking at the Summit. Longevity Summit: https://lnkd.in/gWnVxNQz cc: Ronjon Nag Anastasiya K. (Giarletta) Seifollahi

Join me at the Buck Institute for Research on Aging this Dec 3-4!

It’s a new dawn for Alzheimer’s therapies. Lots of promising interventions coming in the next 1-3 years.

Could brain fat droplets play a role in Alzheimer's? An NIA-funded study found that microglia in the brain may accumulate fat droplets and secrete chemical messengers that damage neurons. The APOE ԑ4 genetic risk variant for Alzheimer’s may exacerbate these harmful changes. Learn more about how fat-filled microglia may play a role in the damage caused by Alzheimer’s: https://lnkd.in/dezEwBGh #NIAFunded #NIHAging #Microglia #Alzheimers

We are very happy to be holding the 4th Annual Longevity Global Summit again this year at the Buck Institute for Research on Aging. If you haven't been there, the Buck is a non-profit research institute in Novato, CA dedicated to research on healthy aging. Their event space and auditorium are absolutely beautiful and they are doing some of the best science around. Big thanks to the Buck and Eric Verdin for hosting us. You can learn more and purchase Summit tickets here: https://lnkd.in/gWnVxNQz

APOE4 allele is the strongest genetic risk factor for Alzheimer's disease. If you are like Chris Hemsworth and have two copies of APOE4, your risk for AD goes up 10-15 fold. Despite this, there are no approved therapies that target APOE directly (and compared to amyloid, a miniscule number of approaches have been tried). One reason is that it's not an easy target to modulate and there is not even consensus on how to modulate it. But we do know that APOE4 is generally associated with increased risk in the Caucasian and Asian populations and less so in African populations. And we also know that APOE2 reduces AD risk. Christin Glorioso, MD PHD and I were recently discussing what would be the best approach to target it and shortly after, Andy Lee informed me of an APOE2 gene therapy approach: https://lnkd.in/eTt63-3X I am in no way associated with Lexeo Therapeutics but I find in fascinating and am curious what my AD friends think of gene therapy with APOE2 (perhaps with simultaneous suppression of APOE4)? Personally, I am a fan of small molecules (in the form of a pill preferably) since you can stop taking them if adverse effects arise but given the lack of those, would you try gene therapy if you had two copies of APOE4?

One of NeuroAge Therapeutics first beta testers, Mike Olson, blogged about his experience taking the NeuroAge Test. For me it was really incredible to hear about his journey. I also have a strong family history of Alzheimer's and one APOE4 allele and we created the test to help people like Mike (and me) prevent the onset of dementia many years in the future. Read his story here: https://lnkd.in/guUHGmTu The NeuroAge Test launch party is December 5th. Everyone is welcome. RSVP: https://lu.ma/8j885iyd "I have a marked family history of age-related neurodegenerative disease. Relatives in the two generations above me have suffered from Alzheimer’s and Lewie Body disease. These conditions are heritable, so of course they concern me. I live my life profoundly between my ears — I enjoy learning and thinking and reading and writing and making things. The prospect of losing those abilities, and losing the memories that they have created, frightens me... So I have this grinding, low-grade worry that my grasp on the world might start to slip. To cope, I spend time reading articles about scientific advances in the field. I keep an eye out for people doing interesting work and connect with them when I can. Early this year, that habit led me to Dr. Christin Glorioso, an MD/PhD with degrees from the University of Pittsburgh School of Medicine and MIT. She’s the founding CEO of NeuroAge Therapeutics. NeuroAge is working on both diagnostics and treatments for Alzheimer’s. The company uses a battery of tests to assess your “brain age” — how your brain compares to the population generally, and to folks who are the same chronological age as you..." Ronjon Nag, Anastasiya K. (Giarletta) Seifollahi, Joshua Langenthal, Joseph Raffaele, MD, Emani H., Persiana Cota, MA, NBC-HWC, Francesco Neri, Lionel Church